In case you missed it: June 20 to June 24
A look back at the week's top stories.
EPA releases new advisories for PFAS levels in drinking water
Essentially no safe levels of toxic ‘forever chemicals’ found in many US water systems.
Relugolix demonstrates positive phase 3 data as combination therapy for endometriosis pain
Results suggest the potential of this oral therapy to address the unmet clinical need for long-term medical treatment for endometriosis.
Evofem Biosciences announces results of post hoc analysis of phase 3 clinical trial data
Evofem Biosciences, Inc. recently announced results of a post hoc analysis of the registrational Phase 3 AMPOWER trial, which investigated the ability of a contraceptive gel consisting of lactic acid, citric acid, and potassium bitartrate (Phexxi; Evofem) to prevent pregnancy.
Berberine promising therapy to treat vulvovaginal candidiasis
Vaginal yeast infections were successfully treated with berberine, a biologically active herbal alkaloid, according to a study published in Frontiers in Pharmacology.
Women with PCOS at increased risk of cardiovascular complications during pregnancy
Using National Inpatient Sample data from a nearly 2 decade period, investigators detail the increased risk of cardiovascular complications among women with PCOS during delivery hospitalizations and predictors of this increased risk.
Exposure to 'forever chemicals' linked to increased risk of hypertension
New research suggests cumulative exposure to PFAS could increase risk of incident hypertension by 71% among midlife women.